Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 6, 2003, Pages 587-594

  Scholten, T ^a   Gatz, G ^b   Hole, U ^b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b ALTANA Pharma   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; PANTOPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENDOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; STATISTICAL SIGNIFICANCE; SYMPTOM;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; QUESTIONNAIRES; SULFOXIDES; TREATMENT OUTCOME;

EID: 0141427803     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01745.x     Document Type: Article

References (33)

1. Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 1621-30.
2. Hixson LJ, Kelley CL, Jones WN, Tuohy CD. Current trends in the pharmacotherapy for gastroesophageal reflux disease. Arch Intern Med 1992; 152: 717-23.
3. Fennerty MB, Castell D, Fendrick AM, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Suggested disease management guidelines. Arch Intern Med 1996; 156: 477-84.
4. Kahrilas PI. Gastroesophageal reflux disease. J Am Med Assoc 1996; 276: 983-8.
5. Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastrooesophageal reflux disease in general practice. Br Med J 2001; 322: 344-7.
6. Kaplan-Machlis B, Spiegler GE, Revicki DA. Health-related quality of life in primary care patients with gastroesophageal reflux disease. Ann Pharmacother 1999; 33: 1032-6.
7. Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996; 221: 8-13.
8. Glise H, Hallerback B, Johansson B. Quality of life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterol Suppl 1995; 208: 133-5.
9. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. J Am Med Assoc 1989; 262: 907-13.
10. Juhani KM, Wahl M, Wiklund I, et al. Acute and long-term effects on myocardial ischemia of intermittent and continuous transdermal nitrate therapy in stable angina. Am J Cardiol 1992; 69: 1525-32.
11. Nissinen A, Wiklund I, Lahti T, et al. Anti-anginal therapy and quality of life. A comparison of the effects of transdermal nitroglycerin and long-acting oral nitrates. J Clin Epidemiol 1991; 44: 989-97.
12. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol 1993; 28(Suppl. 199): 18-21.
13. Ware JE Jr, Kosinski M, Keller SD. SF-36 Health Survey. Manual and interpretation guide. Boston, MA: The Health Institute. New England Medical Center, 1993.
14. Wiklund IK, Junghard O, Grace E, et al. quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur. J Surg. Suppl 1998: 41-9.
15. Colwell HH, Mathias SD, Pasta DJ, Henning JM, Hunt RH. Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease: a validation study. Dig Dis Sci 1999; 44: 1376-83.
16. Raymond JM, Marquis P, Bechade D, et al. [Assessment of quality of life of patients with gastroesophageal reflux. Elaboration and validation of a specific questionnaire]. Gastroenterol Clin Biol 1999; 23: 32-9.
17. Svedlund J, Sjodin I, Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129-34.
18. Johnsson F, Roth Y, Damgaard Pedersen NE, Joelsson B. Cimetidine improves GERD symptoms in patients selected by a validated GERD questionnaire. Aliment Pharmacol Ther 1993; 7: 81-6.
19. Velanovich V, Vallance SR, Gusz JR, Tapia FV, Harkabus MA. Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg 1996; 183: 217-24.
20. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997-2000.
21. Rothman M, Farup C, Stewart W, Helbers L, Zeldis J. Symptoms associated with gastroesophageal reflux disease, development of a questionnaire for use in clinical trials. Dig Dis Sci 2001; 46: 1540-9.
22. Junghard O, Lauritsen K, Talley NJ, Wiklund IK. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non-ulcer dyspepsia. Eur. J Surg. Suppl 1998: 106-11.
23. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
24. Koerner T, Schuetze K. Comparable efficacy of pantoprazole 40 mg vs. omeprazole MUPS 40 mg in patients with GERD II/III. Gut (Suppl III) 2002; 51: A166.
25. van Rensburg CJ, Bardhan KD. No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2001; 13: 909-14.
26. Bardhan KD. Pantoprazole. A new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs Today 1999; 35: 773-808.
27. Thitiphuree S, Talley NJ. Esomeprazole, a new proton pump inhibitor, pharmacological characteristics and clinical efficacy. Int J Clin Pract 2000; 54: 537-41.
28. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.
29. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 119-24.
30. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7: 75-83.
31. Festen HP, Schenk E, Tan G, Snel P, Nelis F. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease, short- and long-term treatment. The Dutch Reflux Study Group. Am J Gastroenterol 1999; 94: 931-6.
32. Vcev A, Stimac D, Vceva A, et al. Pantoprazole versus omeprazole in the treatment of reflux esophagitis. Acta Med 1999; 53: 79-82.
33. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.